West Pharmaceutical Services (WST) Total Non-Current Liabilities (2009 - 2026)

West Pharmaceutical Services' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 18.68% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 18.68% YoY), while the FY2025 annual figure was $1.0 billion, up 13.34% from the prior year.
• Total Non-Current Liabilities came in at $1.0 billion for Q1 2026 at West Pharmaceutical Services, up from $1.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.0 billion in Q1 2026 to a low of $812.1 million in Q3 2022.
• A 5-year average of $901.6 million and a median of $890.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities declined 11.0% in 2022 and gained 18.68% in 2026, its largest moves.
• West Pharmaceutical Services' Total Non-Current Liabilities stood at $880.3 million in 2022, then gained by 1.1% to $890.0 million in 2023, then climbed by 1.0% to $898.9 million in 2024, then climbed by 13.34% to $1.0 billion in 2025, then grew by 1.28% to $1.0 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.0 billion, $1.0 billion, and $979.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison